Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailFin du Millénaire - fin de l'Agriculture
Schirmer, Jacek; Schmitz, Serge ULg

in Bulletin de la Société Géographique de Liège (1997), 33

Detailed reference viewed: 11 (2 ULg)
See detailLa fin du Paléolithique moyen dans le Nord de l’Europe : la question des origines du Lincombien-Ranisien-Jerzmanowicien
Flas, Damien ULg

in Depaepe, Pascal (Ed.) Les plaines du Nord-Ouest : carrefour de l’Europe au Paléolithique moyen ? (in press)

Detailed reference viewed: 20 (1 ULg)
See detailLa fin du théologico-politique chez Hobbes et chez Spinoza
Herla, Anne ULg

Conference given outside the academic context (2005)

Detailed reference viewed: 3 (0 ULg)
See detailLa fin'amor, un art d'aimer au Moyen Âge
Henrard, Nadine ULg

Conference given outside the academic context (2006)

Detailed reference viewed: 25 (5 ULg)
Full Text
Peer Reviewed
See detailFinal analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
DI LEO, Angelo; JERUSALEM, Guy ULg; PETRUZELKA, Lubos et al

in Cancer Research. Supplement (2012, December 15), 72(24), 1-4

Detailed reference viewed: 17 (8 ULg)
Full Text
Peer Reviewed
See detailFinal Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial.
Leo, Angelo Di; Jerusalem, Guy ULg; Petruzelka, Lubos et al

in Journal of the National Cancer Institute (2014), 106(1), 337

BACKGROUND: At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized, double-blind, phase III trial ... [more ▼]

BACKGROUND: At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized, double-blind, phase III trial, approximately 50% of patients had died. A final analysis of OS was subsequently planned for when 75% of patients had died. METHODS: Patients were randomly assigned 1:1 to fulvestrant 500 mg administered as two 5-mL intramuscular injections on days 0, 14, and 28 and every 28 (+/-3) days thereafter or fulvestrant 250 mg administered as two 5-mL intramuscular injections (one fulvestrant and one placebo [identical in appearance to study drug]) on days 0, 14 (two placebo injections only), and 28 and every 28 (+/-3) days thereafter. OS was analyzed using an unadjusted log-rank test. No adjustments were made for multiplicity. Serious adverse events (SAEs) and best response to subsequent therapy were also reported. All statistical tests were two-sided. RESULTS: In total, 736 women (median age = 61.0 years) were randomly assigned to fulvestrant 500mg (n = 362) or 250mg (n = 374). At the final survival analysis, 554 of 736 (75.3%) patients had died. Median OS was 26.4 months for fulvestrant 500mg and 22.3 months for 250mg (hazard ratio = 0.81; 95% confidence interval = 0.69-0.96; nominal P = .02). There were no clinically important differences in SAE profiles between the treatment groups; no clustering of SAEs could be detected in either treatment group. Type of first subsequent therapy and objective responses to first subsequent therapy were well balanced between the two treatment groups. CONCLUSIONS: In patients with locally advanced or metastatic estrogen receptor-positive breast cancer, fulvestrant 500mg is associated with a 19% reduction in risk of death and a 4.1-month difference in median OS compared with fulvestrant 250mg. Fulvestrant 500mg was well tolerated, and no new safety concerns were identified. [less ▲]

Detailed reference viewed: 23 (2 ULg)
See detailFinal Report of the Solar Influences Data Centre Space Weather Pilot Project
Vanlommel, P.; Stegen, Koen; Warnant, René ULg et al

Report (2005)

Detailed reference viewed: 8 (0 ULg)
Full Text
See detailFinal Report on the Belgian Survey on Experience of racial Discrimination
Italiano, Patrick ULg

Report (2003)

The report refers to the Belgian part of an european survey on experience of racial discrimination. The survey was carried out among four communities (Turkish, Morrocan, Chinese and Congolese) in three ... [more ▼]

The report refers to the Belgian part of an european survey on experience of racial discrimination. The survey was carried out among four communities (Turkish, Morrocan, Chinese and Congolese) in three different cities of Belgium (Gent, Brussels, Liege). The result of the survey are analysed in a comparative way between communities and cities. [less ▲]

Detailed reference viewed: 17 (5 ULg)
See detailFINAL REPORT PHASE I "Impact of Phenology and Environmental Conditions on BVOC Emissions from Forest Ecosystems” «IMPECVOC»
Steppe, Kathy; Šimpraga, Maja; Verbeeck, Hans et al

Report (2008)

Detailed reference viewed: 22 (5 ULg)
Full Text
See detailFINAL REPORT PHASE II "Impact of Phenology and Environmental Conditions on BVOC Emissions from Forest Ecosystems" "IMPECVOC"
Dewulf, Jo; Joó, Eva; Van Langenhove, Herman et al

Report (2011)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailFinal results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial.
Duckers, Henricus J.; Houtgraaf, Jaco; Hehrlein, Christoph et al

in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2011), 6(7), 805-12

AIMS: The SEISMIC study was an open-label, prospective, randomised study to assess the safety and feasibility of percutaneous myoblast implantation in heart failure patients with implanted cardioverter ... [more ▼]

AIMS: The SEISMIC study was an open-label, prospective, randomised study to assess the safety and feasibility of percutaneous myoblast implantation in heart failure patients with implanted cardioverter-defibrillators (ICD). METHODS AND RESULTS: Patients were randomised 2:1 to autologous skeletal myoblast therapy vs. optimal medical treatment. The primary safety end-point was defined as the incidence of procedural and device related serious adverse events, whereas the efficacy endpoints were defined as the change in global LVEF by MUGA scan, change in NYHA classification of heart failure and in the distance achieved during a six-minute walk test (6MW) at 6-month follow-up. Forty subjects were randomised to the treatment arm (n=26), or to the control arm (n=14). There were 12 sustained arrhythmic events and one death after episodes of ventricular tachycardia (VT) in the treatment group and 14 events in the control group (P=ns). At 6-month follow-up, 6MW distance improved by 60.3+/-54.1?meters in the treated group as compared to no improvement in the control group (0.4+/-185.7?meters; P=ns). In the control group, 28.6% experienced worsening of heart failure status (4/14), while 14.3% experienced an improvement in NYHA classification (2/14). In the myoblast-treatment arm, one patient experienced a deterioration in NYHA classification (8.0%), whereas five patients improved one or two classes (20.0%; P=0.06). However, therapy did not improve global LVEF measured by MUGA at 6-month follow-up. CONCLUSIONS: These data indicate that implantation of myoblasts in patients with HF is feasible, appears to be safe and may provide symptomatic relief, though no significant effect was detected on global LVEF. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailFinal results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity
Garcia, A; Awada, A; Chan, S et al

in Journal of Clinical Oncology (2011), 29(supplement 27),

Detailed reference viewed: 17 (1 ULg)
Full Text
See detailFinal Session, 31 August 1967
Swings, Polydore ULg

in Transactions of the International Astronomical Union. Series B, Proceedings of the general assembly (1968), 13

Detailed reference viewed: 7 (2 ULg)
See detailI finali nella poesia di raffaello Baldini
Benzoni, Pietro ULg

Scientific conference (2000, May 02)

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailFinalisation de la formule, applicable en Région wallonne, de la distance minimale d'implantation des porcheries et des poulaillers par rapport aux habitations.
Cobut, Pierre; Nicolas, Jacques ULg; Lalande, Dominique et al

Report (2011)

A formulae to calculate the minimum distance between livestock buildings and residential areas was designed by the research group in 2006. This report concerns a study aiming at finalizing the approach ... [more ▼]

A formulae to calculate the minimum distance between livestock buildings and residential areas was designed by the research group in 2006. This report concerns a study aiming at finalizing the approach towards a guideline applicable in Wallonia. Different enhancements to the former formulae are proposed, taking into account recent technical improvements, and a comparison with the odour percentile concept is presented. [less ▲]

Detailed reference viewed: 34 (2 ULg)